ESCITALOPRAM (GENERIC DRUG) IN MAJOR DEPRESSIVE DISORDER (MDD) - BUDGET IMPACT ANALYSIS

被引：0
|
作者：
Walczak, J. [1 ]
Nogas, G. [1 ]
Garbacka, M. [1 ]
Obrzut, G. [1 ]
Pieniazek, I [1 ]
机构：
[1] Arcana Inst, Krakow, Poland
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72523-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A109 / A109
页数：1
相关论文
共 50 条
  • [1] ECONOMIC ANALYSIS OF ESCITALOPRAM (GENERIC DRUG) IN MAJOR DEPRESSIVE DISORDER (MDD)
    Walczak, J.
    Nogas, G.
    Garbacka, M.
    Obrzut, G.
    Pieniazek, I
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A114 - A114
  • [2] Superiority of Escitalopram over Paroxetine in the treatment of Major Depressive Disorder (MDD)
    Kasper, S.
    Baldwin, D.
    Boulenger, J. P.
    [J]. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2008, 12 (04) : 337 - 337
  • [3] THE ECONOMIC IMPACT OF GENERIC SWITCHING FOR PATIENTS WITH MAJOR DESPRESSIVE DISORDER (MDD) TREATED WITH ESCITALOPRAM OR A PATENTED SSRI
    Lauzon, V
    Kaltenboek, A.
    Yu, A. P.
    Ramakrishnan, K.
    Marynchenko, M.
    Wu, E. Q.
    Ben-Hamadi, R.
    Erder, M. H.
    Bose, A.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A179 - A179
  • [4] COMPARATIVE ANALYSIS OF THE EFFICACY AND SAFETY OF ESCITALOPRAM WITH SERTRALINE AND VENLAFAXINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
    Walczak, J.
    Malysiak, S.
    Rowinska, M.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A107 - A107
  • [5] A pharmacoeconomic comparison of escitalopram and duloxetine in treatment of major depressive disorder (MDD) in the United Kingdom
    Wade, A. G.
    Fernandez, J. L.
    Francois, C.
    Hansen, K.
    Despiegel, N.
    Danchenko, N.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A306 - A306
  • [6] COMPARISON OF HOSPITALIZATIONS AND HEALTH CARE COSTS OF ELDERLY MAJOR DEPRESSIVE DISORDER (MDD) PATIENTS TREATED WITH ESCITALOPRAM, GENERIC SSRIS, OR SNRIS
    Wu, E. Q.
    Cahill, K. E.
    Bieri, C.
    Ben-Hamadi, R.
    Yu, A. P.
    Erder, M. H.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A179 - A179
  • [7] Escitalopram and paroxetine in the short and long-term treatment of major depressive disorder (MDD)
    Baldwin, D
    Hindmarch, I
    Huusom, AKT
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S168 - S169
  • [8] BUDGET IMPACT ANALYSIS OF DULOXETINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER
    Gwiosda, B.
    Rutkowski, J.
    Rys, P.
    Plisko, R.
    Wladysiuk, M.
    Cel, M.
    Mierzejewski, P.
    Bartminski, W.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A354 - A354
  • [9] Pooled analysis of two randomised clinical trials of escitalopram and paroxetine fit the treatment of major depressive disorder (MDD)
    Kasper, S.
    Baldwin, D.
    Boulenger, J. -P.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 193 - 193
  • [10] ECONOMIC ASSESSMENT OF SECOND-LINE TREATMENT: SWITCHING FROM A GENERIC SSRI TO ESCITALOPRAM, AN SNRI, OR ANOTHER GENERIC SSRI BY PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
    Marynchenko, M.
    Yu, A. P.
    Lauzon, V
    Ramakrishnan, K.
    Wu, E. Q.
    Ben-Hamadi, R.
    Erder, M. H.
    Bose, A.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A175 - A176
12345